U.S. Markets closed
  • S&P Futures

    4,464.33
    -9.92 (-0.22%)
     
  • Dow Futures

    34,696.80
    -52.20 (-0.15%)
     
  • Nasdaq Futures

    15,486.67
    -31.08 (-0.20%)
     
  • Russell 2000 Futures

    2,241.04
    +7.84 (+0.35%)
     
  • Crude Oil

    71.76
    -0.21 (-0.29%)
     
  • Gold

    1,753.70
    +2.30 (+0.13%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1729
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3727
    -0.0011 (-0.0769%)
     
  • USD/JPY

    110.0310
    +0.1360 (+0.1238%)
     
  • BTC-USD

    47,168.87
    -1,025.09 (-2.13%)
     
  • CMC Crypto 200

    1,182.20
    -43.33 (-3.54%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Sanofi Invests To Build Internal Capabilities in mRNA

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines.

  • The company will invest approximately €400 million per year to build out its “end-to-end” internal capabilities in mRNA, the cell therapy technology.

  • Sanofi said the plan is to piece together a team of around 400, spread across R&D, digital, chemistry, manufacturing & controls to advance mRNA technology in non-pandemic indications.

  • The team will be spread across two centers in Cambridge, MA, and Marcy l’Etoile, near Lyon, France.

  • With this investment, Sanofi hopes to have six clinical candidates in the fold by 2025, which it calls the “expected minimum.”

  • Though it did not disclose the therapeutic areas it hoped to address, the company said its focus would be on “diseases of high unmet need.”

  • Price Action: SNY shares are down 1% at $52.69 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.